Industry Sponsored Symposia |
A Practical Approach to Treating HCV in PWID |
|
When? Wednesday 7 September, 12.15pm - 1.15pm
Where? Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel
Cost? Included in your delegate registration
Symposium Synopsis
MSD is pleased to present a symposium entitled “A Practical Approach to Treating HCV in PWID.” An internationally renowned faculty chaired by Olav Dalgard will present emerging data on the treatment HCV in PWID. The first lecture by Mojca Maticic will focus on treatment considerations of the PWID including the quality of life of PWIDs, continued drug use, reinfection and barriers to treatment. The second lecture by Ashley Brown will review underlying comorbidities in PWID including an discussion on common co-morbidities such as co-infection, psychiatric conditions and extra-hepatic manifestations in younger vs older PWID, gender differences in co-morbidities and how to manage co-morbidities to ensure a successful treatment.
Making HCV Elimination a Reality for PWID |
|
When? Thursday 8 September, 12.15pm - 1.15pm
Where? Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel
Cost? Included in your delegate registration
Symposium Synopsis
With HCV cure rates of more than 90%, the direct-acting antiviral agents afford the opportunity to eliminate HCV infection from groups of affected patients. In medium-to-high income countries people who inject drugs are disproportionately affected by HCV. Low HCV treatment uptake among people who inject drugs indicate that these patients come up against many challenges in accessing HCV treatment and care. In this educational symposium the faculty will be focusing on what is being done from a global policy perspective and what needs to be done at a country level to make HCV elimination a reality
TREAT TO CURE. TREAT TO PREVENT. Management of Substance Users with HCV Infection |
![]() |
When? Friday 9 September, 12.15pm - 1.15pm
Where? Scandinavia Ballroom, Radisson Blu Scandinavia Hotel
Cost? Included in your delegate registration
Symposium Synopsis
The past decade has seen unprecedented advances in hepatitis C treatment with new highly effective all-oral interferon-free direct-acting antiviral therapies. Drug users have traditionally been a challenging patient population to treat and can be at risk of reinfection following successful treatment.
This cutting-edge AbbVie-sponsored symposium will cover topics ranging from current treatment options and access to care, to treatment to prevent the spread of hepatitis C in people who use drugs.
We would be delighted to invite you to this symposium with some of the world’s leading experts in the field of viral hepatitis. With the opportunity to pose questions to the panel, this debate-style symposium promises to be an interactive and educational meeting that will address a wide range of issues facing physicians today.
This cutting-edge AbbVie-sponsored symposium will cover topics ranging from current treatment options and access to care, to treatment to prevent the spread of hepatitis C in people who use drugs.
We would be delighted to invite you to this symposium with some of the world’s leading experts in the field of viral hepatitis. With the opportunity to pose questions to the panel, this debate-style symposium promises to be an interactive and educational meeting that will address a wide range of issues facing physicians today.